A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Eltrombopag (Primary) ; Antithymocyte globulin; Ciclosporin
- Indications Aplastic anaemia
- Focus Pharmacokinetics
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 29 Jul 2017 Planned End Date changed from 26 Dec 2023 to 25 Mar 2024.
- 29 Jul 2017 Planned primary completion date changed from 26 Dec 2023 to 25 Mar 2024.
- 29 Jul 2017 Planned initiation date changed from 30 Jun 2017 to 30 Sep 2017.